Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Vivos is a medical technology company pivoting from a legacy dentist-focused model to a medical-provider focused sales and distribution model. This strategy involves acquiring sleep centers, such as The Sleep Center of Nevada (SCN) in June 2025, to directly manage patient diagnostics and treatment for obstructive sleep apnea (OSA) using proprietary oral appliances.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $5.15 million | $10.29 million |
| Gross Profit | $2.95 million (57% margin) | $6.01 million (58% margin) |
| Operating Loss | $(4.83) million | $(11.44) million |
| Net Loss | $(5.52) million | $(13.27) million |
| Cash and Cash Equivalents | $1.77 million (as of June 30, 2026) | |
| Total Liabilities | $28.13 million | |
| Stockholders' Equity (Deficit) | $(3.82) million |
Debt Profile: As of June 30, 2026, the company held approximately $8.4 million in principal note payable balances (excluding equipment financing), with significant current portions due. The company also carries contingent consideration liabilities related to the SCN acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 35% ($1.33 million) for the three months ended June 30, 2026, compared to the same period in 2025. This was driven by a $1.86 million increase in service revenue (primarily sleep testing and treatment center services from SCN), which offset a $0.53 million decline in product revenue.
- Product Mix Shift: Product revenue declined due to a decrease in high-margin appliance sales to VIPs, partially offset by increased sales of lower-revenue preformed appliances and diagnostic reports.
- Expense Increases: General and administrative expenses rose 11% ($0.7 million) for the quarter, driven by salaries and rent associated with the SCN acquisition and new treatment centers. Operating expenses increased significantly due to the integration of SCN operations.
- Net Loss Expansion: Net loss increased by $0.51 million for the quarter and $4.40 million for the six-month period, primarily due to higher operating costs and interest expenses on debt incurred to finance the SCN acquisition.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: The filing explicitly states that cash on hand ($1.77 million) is insufficient to fund operations for the next 12 months. Management has raised substantial doubt regarding the company's ability to continue as a going concern without additional financing.
- Financing Activities: The company closed a $2.1 million private placement (PIPE) in June 2026 involving Series A Convertible Preferred Stock and warrants. It also engaged in warrant exercises and debt conversions to bolster liquidity.
- Nasdaq Compliance: The company is not in compliance with Nasdaq's minimum stockholders' equity requirement ($2.5 million) and minimum bid price requirement. It has submitted a plan to regain compliance, with a potential extension through October 14, 2026.
- Strategic Risks: The new medical-provider model is unproven. Risks include the inability to scale the SCN model, challenges in insurance reimbursement, and the high cost of servicing debt incurred for the acquisition.
- Legal Settlement: In March 2026, the company settled litigation with Ortho-Tain, Inc., agreeing to a confidential payment and restrictions on using the term "Guide" in product names.
- Subsequent Events: Following the period end, the company entered into short-term loans with an effective interest rate of approximately 38% and completed a debt-for-equity exchange with Streeterville Capital, LLC.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.77 million cash balance against the stated $9.2 million operating cash burn for the six-month period.
- Debt Covenants: Review the terms of the $8.3 million note payable and the Streeterville Capital exchange agreement for immediate repayment triggers or restrictive covenants.
- Nasdaq Status: Monitor the acceptance of the compliance plan and the company's ability to raise the required equity to meet the $2.5 million stockholders' equity threshold by October 2026.
- Revenue Sustainability: Assess whether the revenue growth from SCN services is sustainable and if it can offset the decline in legacy product sales.
- Subsequent Financing: Confirm the terms and impact of the post-period short-term loans (38% interest rate) and the debt-for-equity swap on future dilution and cash flow.